August 2012
-
RDD 2024, which took place May 5-9 in Tucson, AZ, USA, brought together more than 530 delegates and 70 exhibitors for a meeting that highlighted a number of transitions taking place in the development of OINDPs. Compared… Read more . . .
-
Gerresheimer has announced a $180 million, 194,000 sq ft expansion of its device manufacturing facilities near Atlanta, GA, USA. The company says that the expansion will create more than 400 new jobs at its Georgia… Read more . . .
-
Ferrer has announced that its 2022 agreement with United Therapeutics for distribution rights to Tyvaso treprostinil inhalation solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) outside of the US, Canada,… Read more . . .
-
According to Rigshospitalet spin-out Cessatech, the company has initiated a Phase 3 trial of its CT001 sufentanil / ketamine nasal spray in children seen in the emergency department with moderate to severe pain. In July… Read more . . .
-
Amphastar Pharmaceuticals announced that the FDA has approved the company’s ANDA for a generic version of Teva’s ProAir HFA albuterol MDI for the treatment of asthma and said that it plans to launch the inhaler in… Read more . . .
-
Celon Pharma has disclosed a deal in which it will invest $20 million over 2 years, and Tang Capital will invest $10 million over that same period, in a new US-based company called Novohale Therapeutics… Read more . . .
-
TFF Pharmaceuticals announced the Cleveland Clinic Florida will perform additional preclinical studies of 3 dry powder hemagglutinin antigen/adjuvent vaccine candidates produced under a 2023 SBIR grant to TFF for preclinical development of a dry powder… Read more . . .
-
According to Inimmune, a Phase 1b trial of its INI-2004 TLR4 agonist in people with allergic rhinitis demonstrated dose dependent reduction of nasal congestion compared to placebo in a ragweed challenge test, with a reduction… Read more . . .
-
EVŌQ Bio said that it had positive feedback from the FDA following a pre-IND meeting about EVQ-218 inhaled non-ionic silver nanoparticle, which the company is developing for the treatment of pulmonary bacterial infections in cystic… Read more . . .
-
DPI developers Iconovo have announced plans to develop inhaled GLP-1 receptor agonists for the treatment of obesity and, potentially, related metabolic diseases. The company says that it plans to conduct preclinical proof-of-concept studies itself and… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.